J. Jean Cui
Hebei Agricultural University(CN)Tongji Hospital(CN)Huazhong University of Science and Technology(CN)Southern Medical University(CN)Dalian Polytechnic University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms, RNA modifications and cancer, Lung Cancer Research Studies, Autism Spectrum Disorder Research
Most-Cited Works
- → Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)(2011)909 cited
- → Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations(2014)574 cited
- → Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations(2018)469 cited
- → N6-Methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2(2020)261 cited
- → Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib(2014)117 cited